Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Interest & Investment Income (2016 - 2018)

VYNE Therapeutics (VYNE) has disclosed Interest & Investment Income for 3 consecutive years, with $825000.0 as the latest value for Q2 2018.

  • For the quarter ending Q2 2018, Interest & Investment Income rose 1045.83% year-over-year to $825000.0, compared with a TTM value of $1.8 million through Jun 2018, changed N/A, and an annual FY2017 reading of $517000.0, up 487.5% over the prior year.
  • Interest & Investment Income was $825000.0 for Q2 2018 at VYNE Therapeutics, up from $563000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $825000.0 in Q2 2018 and bottomed at $72000.0 in Q2 2017.
  • Average Interest & Investment Income over 3 years is $284714.3, with a median of $163000.0 recorded in 2017.
  • The sharpest move saw Interest & Investment Income skyrocketed 128.41% in 2017, then soared 1045.83% in 2018.
  • Year by year, Interest & Investment Income stood at $88000.0 in 2016, then surged by 128.41% to $201000.0 in 2017, then surged by 310.45% to $825000.0 in 2018.
  • Business Quant data shows Interest & Investment Income for VYNE at $825000.0 in Q2 2018, $563000.0 in Q1 2018, and $201000.0 in Q4 2017.